Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis.
Fiche publication
Date publication
mars 2021
Journal
Drug safety
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Lasa JS, Olivera PA, Bonovas S, Danese S, Peyrin-Biroulet L
Lien Pubmed
Résumé
Sphingosine-1-phosphate modulators are approved for the treatment of multiple sclerosis and are under development for other immune-mediated conditions; however, safety concerns have arisen.
Référence
Drug Saf. 2021 Mar 5;: